engleski

CD43 Expression Is an Adverse Prognostic Factor in Diffuse Large B-Cell Lymphoma

CD43 is a transmembrane glycoprotein expressed in different haematopoietic cells including some subsets of B lymphocytes. About a quarter of diffuse large B-cell lymphomas (DLBCL) express CD43 but its prognostic significance is unknown. We analyzed the prognostic impact of immunohistochemically determined CD43 expression in 119 patients with newly diagnosed DLBCL. All were treated with CHOP-like chemotherapy, 57 without and 62 with rituximab. Median follow-up was 31 months. Thirty-one (26%) DLBCLs expressed CD43. Patients with CD43+ and CD43- lymphomas did not differ regarding gender, IPI factors and score, rituximab treatment, presence of bulky disease or germinal centre subtype. Patients with CD43+ DLBCL had significantly lower complete response rate (59% vs 80%, p= .019), 2-year event-free survival (EFS) (34% vs 64%, p=.003), and overall survival (OS) (45% vs 76%, p=.002). The prognostic significance of CD43 expression was retained in multivariate analysis (RR 2.04, p=.013 for EFS ; RR 2.17, p=.016 for OS). In subgroup analysis, the effect of CD43 expression was significant in patients treated with rituximab and those with low IPI while it was not reached in patients treated without rituximab. The effect was not observed in patients with high IPI. CD43 expression is an important independent adverse prognostic factor in DLBCL.

CD43; rituximab; CHOP; diffuse large B-cell lymphoma; glycoproteins

nije evidentirano